Masaki Muramatsu

Dr. Masaki Muramatsu

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Transplantation
Verified
Journal Article
Open access
MMMasaki Muramatsu
Masaki Muramatsu
HGHector Daniel Gonzalez
Hector Daniel Gonzalez
RCRoberto Cacciola
Roberto Cacciola
AAAtsushi Aikawa
Atsushi Aikawa
MYMagdi M Yaqoob
Magdi M Yaqoob
CPCarmelo Puliatti
Carmelo Puliatti
ABO incompatible kidney transplantation (ABOi-KT) was previously considered to be an absolute contraindication for patients with end-stage kidney disease (ESKD) due to hyperacute rejection related to blood type barrier. Since the first successful series of ABOi-KT was reported, ABOi-KT is performed increasingly all over the world. ABOi-KT has led to an expanded donor pool and reduced the number of patients with ESKD awaiting deceased kidney transplantation (KT). Intensified immunosuppression and immunological understanding has helped to shape current desensitization protocols. Consequently, in recent years, ABOi-KT outcome is comparable to ABO compatible KT (ABOc-KT). However, many questions still remain unanswered. In ABOi-KT, there is an additional residual immunological risk that may lead to allograft damage, despite using current diverse but usually intensified immunosuppressive protocols at the expense of increasing risk of infection and possibly malignancy. Notably, in ABOi-KT, desensitization and antibody reduction therapies have increased the cost of KT. Reassuringly, there has been an evolution in ABOi-KT leading to a simplification of protocols over the last decade. This review provides an overview of the history, outcome, protocol, advantages and disadvantages in ABOi-KT, and focuses on whether ABOi-KT should be recommended as a therapeutic option of KT in the future.

27 March 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MMMasaki Muramatsu
Masaki Muramatsu
TMToshihide Mizutani
Toshihide Mizutani
YHYuko Hamasaki
Yuko Hamasaki
YTYusuke Takahashi
Yusuke Takahashi
YIYoshihiro Itabashi
Yoshihiro Itabashi
SSSeiichiro Shishido
Seiichiro Shishido

27 October 2004 in International Journal of Urology
Verified
Journal Article
Open access
PDF file
MMMasaki Muramatsu
Masaki Muramatsu
MMMoriatsu Miyagi
Moriatsu Miyagi
YIYukio Ishikawa
Yukio Ishikawa
AAAtsushi Aikawa
Atsushi Aikawa
SMSonoo Mizuiri
Sonoo Mizuiri
AHAkira Hasegawa
Akira Hasegawa
Background: Various invasive and non‐invasive methods have been investigated for their prognostic value in predicting the outcome of renal allografts. In the present study, vimentin expression in tubular epithelial cells (TEC) was determined by the immunohistochemical examination of biopsy specimens and the prognostic value of this method was assessed. Methods: Ninety‐two renal transplant recipients were recruited for the present study. Protocol biopsy of the renal graft was performed 1, 3 and 5 years after transplantation in each case. All biopsy specimens were treated with conventional stains and immunostained with an antivimentin antibody. The correlation between vimentin expression and glomerular filtration rate (GFR) and the association between vimentin expression and histopathological findings were determined. Results: Vimentin was localized in TEC adjacent to interstitial lesions with lymphocyte infiltration and also in TEC with tubulitis or in atrophic tubules. Vimentin positivity significantly correlated with GFR and both vimentin positivity and GFR were significantly associated with the extent of chronic allograft nephropathy, but not with acute rejection. Additionally, vimentin expression and GFR 3 and 5 years after transplantation were higher in cases where graft loss occurred between 5 and 7 years after transplantation compared with graft survival cases. Conclusions: These results suggest that immunohistochemistry using antivimentin antibodies on protocol biopsy specimens is useful for the detection of injured TEC and as a predictor of allograft outcome.

5 December 2022 in Pediatric Transplantation
Verified
Journal Article
Closed access
MKMai Kubota
Mai Kubota
YHYuko Hamasaki
Yuko Hamasaki
JHJunya Hashimoto
Junya Hashimoto
YAYujiro Aoki
Yujiro Aoki
TKTakeshi Kawamura
Takeshi Kawamura
KSKen Sakai
Ken Sakai

24 August 2020 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
YHYuko Hamasaki
Yuko Hamasaki
RHRiku Hamada
Riku Hamada
MMMasaki Muramatsu
Masaki Muramatsu
SMShinsuke Matsumoto
Shinsuke Matsumoto
KAKunihiko Aya
Kunihiko Aya
KIKazumoto Iijima
Kazumoto Iijima
Background: Congenital nephrotic syndrome (CNS) and infantile nephrotic syndrome (INS) cause substantial morbidity and mortality. In Japan, there is a lack of knowledge regarding the characteristics of CNS and INS. This study aimed to clarify the characteristics of CNS and INS in Japan. Methods: This cross-sectional nationwide survey obtained data from 44 institutions in Japan managing 92 patients with CNS or INS, by means of two survey questionnaires sent by postal mail. Patients aged < 16 years by 1 April 2015, with a diagnosis of CNS or INS, were included in this study. The primary outcome was end-stage kidney disease. Results: A total of 83 patients with CNS or INS were analyzed. The most frequent disease type was non-Finnish (60.2%); 33 patients (39.8%) had Finnish type. Among those with non-Finnish-type disease, 26 had no syndrome and 24 had a syndrome, of which the most frequent was Denys–Drash syndrome (70.8%). Patients with non-Finnish-type disease with syndrome showed the earliest progression to end-stage kidney disease compared with the other two groups, whereas patients with non-Finnish-type disease without syndrome progressed more slowly compared with the other two groups. In the Finnish-type group, the disease was diagnosed the earliest; a large placenta was reported more frequently; genetic testing was more frequently performed (93.8%); mental retardation was the most frequent extra-renal symptom (21.2%); and thrombosis and infection were more frequent compared with the other groups. Patients with non-Finnish-type disease with syndrome had a higher frequency of positive extra-renal symptoms (79.2%), the most common being urogenital symptoms (54.2%). Treatment with steroids and immunosuppressants was more frequent among patients with non-Finnish-type disease without syndrome. Two patients with non-Finnish-type disease without syndrome achieved complete remission. In all groups, unilateral nephrectomy was performed more often than bilateral nephrectomy and peritoneal dialysis was the most common renal replacement therapy. Conclusions: The present epidemiological survey sheds light on the characteristics of children with CNS and INS in Japan. A high proportion of patients underwent genetic examination, and patient management was in accord with current treatment recommendations and practices. Trial registration: Not applicable.

1 June 2018
Verified
Journal Article
Closed access
MMMasaki Muramatsu
Masaki Muramatsu
YHYoji Hyodo
Yoji Hyodo
MSMichael Sheaff
Michael Sheaff
AGArun Gupta
Arun Gupta
NANeil Ashman
Neil Ashman
CPCarmelo Puliatti
Carmelo Puliatti
Objectives: The impact of allograft nephrectomy on the outcome of a subsequent renal transplant is unclear. This study was conducted to assess the effects of the first allograft nephrectomy on outcomes of a second transplant. Materials and Methods: This study included 118 patients who received a second transplant between 1994 and 2015. Before the second transplant, 59 patients did not undergo a first allograft nephrectomy (group A). Group B comprised 59 patients who had undergone a first allograft nephrectomy. We compared sensitization, acute rejection, and survival of the second graft between groups. The risk factors of a second graft loss were assessed. Results: The first graft survival was significantly longer in group A than in group B (100.6 vs 3.7 months; P < .001). Prevalence of preformed donor-specific antibodies before the second allograft was similar between both groups (28.8% vs 39.0% for group A vs group B; P = .243). Numerically higher acute rejection rates occurred in group B than in group A (23.7% vs 15.3%; P = .245). In group A, graft survival rates at 1, 3, and 5 years were 93.0%, 87.0%, and 82.3% and were significantly higher than for group B (76.7%, 69.1%, and 62.5%; P < .05). On multivariate analysis, survival of the second graft was affected by acute rejection (hazard ratio = 2.24; 95% confidence interval, 1.10-4.45; P = .027) and the interval from first graft loss to second transplant (hazard ratio = 1.11; 95% confidence interval, 1.02-1.19; P= .008). Conclusions: A first allograft nephrectomy was associated with inferior second graft survival. We recommend that recipients of second transplants should be considered as high risk if they had undergone prior allograft nephrectomy.